Clinical Trial

Nicotinamide Riboside Supplementation and Exercise Training to Promote Healthy Longevity

Study acronym: RESTORENAD
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 11, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The prevalence of age-related chronic diseases (like obesity, type 2 diabetes and cardiovascular diseases) is mounting worldwide, reaching pandemic proportions. These age-related chronic diseases are associated with diminished skeletal muscle mitochondrial function in humans. Nicotinamide adenosine dinucleotide (NAD) is a coenzyme that regulates mitochondrial function, therefore, plays an important role in energy metabolism. Importantly, it has been shown that high cellular NAD+ levels as well as a high NAD+/NADH ratio promote metabolic and mitochondrial health. In contrast, NAD+ bioavailability declines upon aging in humans as well as in animal models of metabolic disorders and type 2 diabetes. These findings fuel the notion of boosting the NAD+ bioavailability in order to improve metabolic disturbances and mitochondrial dysfunction in aged individuals. Supplementation with nicotinamide riboside (NR), a naturally occurring form of vitamin B3, boosts cellular NAD+ levels. However, in contrast to animal studies, NR supplementation in humans has so far been unsuccessful in improving skeletal muscle mitochondrial function, exercise capacity or insulin sensitivity. Interestingly, Recently, it has been suggested that metabolic conditions where NAD+ levels become limited, is needed for NR supplementation to exert beneficial health effects. This metabolic condition could be achieved by exercise. However, studies combining NR and exercise are lacking, and that is why we will perform the present study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-17.
Trial Details
NCT Number NCT06425042
Lead Sponsor Finis Terrae University
Conditions Healthy Aging, Lifestyle-related Condition, Metabolic Diseases
Enrollment 28 participants
Start Date 2024-03-01
Primary Completion 2025-12 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-07-11